

FOR IMMEDIATE RELEASE

**Completed Last Patient Follow-up in Clinical Study on
Acetyl L-Carnitine Tablets for treatment of Peripheral Neuropathy**

Hong Kong, July 20 , 2011—Lee's Pharmaceutical Holdings Limited (Main Broad Stock: 950: Website: www.leespharm.com) today announced the completion of 4 month follow-up of 236 patients on Sigma-Tau's original product, **Nicetile**[®] (Levocarnitine Acetyl Hydrochloride Gastro-Resistant Tablets, "ALC"), to evaluate the effectiveness and safety for treatment of peripheral neuropathy induced by chemotherapy in Chinese patients.

This multi-centers, randomized, double-blind, placebo-controlled and parallel clinical trial was conducted over 13 major clinical centers located in Beijing, Shanghai, Nanjing, Changzhou and Zhejiang; and led by The 6th People's Hospital affiliated to Shanghai Jiao Tong University. Enrollment for the ALC study was initiated in the summer of 2008, and was completed in April 2011. The patients were evaluated over a 4-month follow-up period and the last patient completed the follow-up assessment to date.

"Completion of the ALC study marks a major milestone of the Group's young clinical development history," said Dr. Benjamin Li, the Chief Executive Officer of the Company. "Oncology has become one of the focused areas of the Group and chemotherapy induced peripheral neuropathy ("CIPN") is a significant unmet medical need in cancer supporting care. We really look forward to the unblind of the study and publishing of the results in one month time. "

Acetyl L-carnitine, a member of Carnitine family, is a kind of short-chain acyl-L-carnitine. Acetic ester of L-carnitine, as low-molecular-mass water-soluble polymers, is widely distributed in tissues of mammals. Acetyl L-Carnitine can acetylate different microtubulins in neurons to enhance the stability of microtubules, prevent cytoskeleton damages and nerve fiber denaturation, so as to improve sensory nerve condition. Nicetile[®] has been launched in Italy since July 1984. Registered indications of ALC were mechanical and inflammatory injuries of peripheral nerve trunks or nerve roots.

It is an important step for the Group to achieve the completion of the follow-up assessment in the ALC trial as a multi-centers trial focused on Chemotherapy-induced peripheral neuropathy ("CIPN") in China. The Group is looking forward to having the study report ready for filing to the SFDA and the application for marketing authorization expected some time in October.

FOR IMMEDIATE RELEASE

About Chemotherapy-induced Peripheral Neuropathy (CIPN)

Chemo-induced peripheral neuropathy (CIPN) is caused by some chemotherapy drugs widely used in cancer treatment. Symptoms are related to the type of nerve that is affected by the chemotherapy., Patients most often experience sensory symptoms such as numbness, tingling, or burning sensations as well as pain and other symptoms related to motor nerve degeneration, even though to a lesser extent.

CIPN may severely affect treatment compliance and thus limit the potential efficacy of the chemotherapeutic regimen. Little or no effective cure is currently available for CIPN

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 16 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products. Lee's Pharma focuses on several key therapeutics areas such as cardiovascular and infectious diseases, dermatology, oncology and gynecology. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from 18 U.S, European and Japanese companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharma is available on the internet at www.leespharm.com.

About Sigma-Tau

Sigma-Tau is a leading, all Italian capital, International pharmaceutical group that invests in the research, development and marketing of innovative and effective treatments to improve human well-being and quality of life. Sigma-Tau Group has headquarters in Pomezia (Rome, Italy), and subsidiaries in France, Switzerland, the Netherlands, Belgium, Portugal, Germany, UK, India, US and Spain, these two latter with a production plant. It has over 2400 employees and an extensive network of licensees worldwide. Sigma-Tau was founded in Italy in 1957 and achieved a global turnover of € 673 million in 2010. Sigma-Tau invests on average 16% of its turnover in R&D, and employs approximately 400 researchers currently working on a significant discovery pipeline, studying, through clinical and pre-clinical trials, 26 different molecules, mostly (11) new and original, and 18 owned by the



FOR IMMEDIATE RELEASE

sigma-tau Group. Therapeutic areas in which the company's research and development are focused include rare and neglected diseases, oncology, immunology and biotech. Website: www.sigma-tau.it

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com